RetinalGenix Technologies Inc. is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. The Company's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimerâ€™s disease and Parkinsonâ€™s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. It is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimerâ€™s syndrome dementia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed OTC Markets 20:38:36 04/05/2026 +04			5-day change	1st Jan Change
4.000 ^USD	+25.00%		-.--%	+25.00%

08-15	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-21	RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	75.37M 64.66M 60.37M 55.39M 104M 7.2B 106M 712M 279M 3.61B 283M 277M 11.95B	P/E 2024	-21.8x	P/E 2025	-24.5x
Enterprise Value	75.9M 65.11M 60.8M 55.78M 105M 7.26B 107M 717M 281M 3.64B 285M 279M 12.03B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	34.7%	Yield 2024 *	-	Yield 2025	-

08-15	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-21	RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt	CI
03-27	Retinalgenix Technologies Inc. Announces Resignation of Michael Cory Zwerling as Chief Financial Officer, Effective March 22, 2026	CI
01-14	RetinalGenix Technologies Inc. Reports on Its Science and Mission in Light of New AI-Driven Retinal Mapping Study	CI
12-09	RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Chief Financial Officer, Effective January 1, 2026	CI
12-09	RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Interim Chief Operating Officer, Effective January 1, 2026	CI
11-15	RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
01/10/25	RetinalGenix Technologies Inc. and RGEN Inc. Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases	CI
01/10/25	RetinalGenix and RGEN Clinical Genotyping Lab partner to advance early disease detection	RE
20/08/25	RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
28/06/25	RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening	CI

01-14	RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study	GL
12-09	RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO	GL
01/10/25	RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases	GL
25/09/25	RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care	GL
30/06/25	RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening	AQ

RetinalGenix Technologies Inc. Stock

Stocks

RTGN

US76133Y1055

Biotechnology & Medical Research

Valuation: RetinalGenix Technologies Inc.

Chart: RetinalGenix Technologies Inc.

Latest news : RetinalGenix Technologies Inc.

Press Releases: RetinalGenix Technologies Inc.

News in other languages: RetinalGenix Technologies Inc.

Quotes and Performance

Course Extremes

Managers and Directors: RetinalGenix Technologies Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Current year	4	4
1 year	3.2	4.01
3 years	0.25	6.36
5 years	0.25	20
10 years	0.25	20

Director	Title	Age	Since
Jerry Katzman CHM	Chairman	73	01/12/2018
Herbert Gould BRD	Director/Board Member	97	01/04/2019
Vinay Mehindru BRD	Director/Board Member	58	26/07/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RETINALGENIX TECHNOLOGIES INC.	+25.00%	-.--%	+12.99%	-57.45%	75.37M
LONZA GROUP AG	+2.37%	+2.30%	+3.39%	+23.26%	48.63B
REVOLUTION MEDICINES, INC.	-1.00%	+4.11%	+484.84%	+615.43%	46.3B
BEONE MEDICINES AG	+1.68%	+4.59%	+20.17%	+91.48%	41.97B
IQVIA HOLDINGS INC.	+3.36%	+2.78%	+29.16%	+15.89%	39.51B
CELLTRION, INC.	-0.72%	-7.79%	+17.87%	+47.98%	31.75B
MEDPACE HOLDINGS, INC.	+2.24%	+1.25%	+30.80%	+145.74%	16.48B
ASCENDIS PHARMA A/S	+2.26%	-0.93%	-	-	16.34B
EUROFINS SCIENTIFIC SE	+1.44%	+1.52%	+4.22%	+31.44%	14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.85%	+2.36%	+83.68%	+44.89%	13.33B
Average	+4.02%	-0.54%	+76.35%	+106.52%	26.84B
Weighted average by Cap.	+1.44%	-0.05%	+106.57%	+154.94%

	2024	2025
Net sales	-	-
Net income	-4.32M -3.71M -3.46M -3.18M -5.97M -413M -6.07M -40.84M -15.99M -207M -16.22M -15.87M -685M	-2.43M -2.08M -1.95M -1.78M -3.36M -232M -3.41M -22.95M -8.99M -116M -9.12M -8.92M -385M
Net Debt	518K 445K 415K 381K 716K 49.54M 728K 4.9M 1.92M 24.84M 1.95M 1.9M 82.14M	530K 455K 425K 389K 732K 50.66M 744K 5.01M 1.96M 25.41M 1.99M 1.95M 84M